According to a recent LinkedIn post from Truveta, a CDC-led study using Truveta Data examined more than 4 million antihypertensive prescriptions and found that patients seen later in the day were less likely to fill their prescriptions. The post indicates that this pattern also extended to maintaining adherence over the following 90 days.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that routine clinical workflows and appointment timing, not only patient behavior, may play a significant role in medication management. For investors, this underscores Truveta’s positioning as a data partner capable of supporting large-scale, real-world evidence research that can inform care delivery, potentially enhancing the company’s strategic value to health systems and public health agencies.
By highlighting CDC-led research based on its dataset, the post implicitly points to the scale and clinical depth of Truveta’s platform. This type of high-impact, outcomes-focused use case may support customer retention and new partnerships, and could strengthen Truveta’s competitive standing in the real-world data and health analytics market over the long term.